Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Praloran, V' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 106 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Francois, B; Trimoreau, F; Desachy, A; Besse, A; Rangez, S; Praloran, V; Vignon, P
      Haemophagocytosis during multiple organ failure: M-CSF overproduction or viral reactivation?

      ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION
    2. Champelovier, P; Besse, A; Boucard, N; Simon, A; Leroux, D; Pinel, N; Praloran, V; Seigneurin, D
      DAG-1 carcinoma cell in studying the mechanisms of progression and therapeutic resistance in bladder cancer

      EUROPEAN UROLOGY
    3. Le Meur, Y; Lorgeot, V; Comte, L; Szelag, JC; Aldigier, JC; Leroux-Robert, C; Praloran, V
      Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: Relationship with erythropoietin requirements

      AMERICAN JOURNAL OF KIDNEY DISEASES
    4. Desplat, V; Ivanovic, Z; Dupuis, F; Faucher, JL; Denizot, Y; Praloran, V
      Effects of lipoxygenase metabolites of arachidonic acid on the growth of human blood CD34(+) progenitors

      BLOOD CELLS MOLECULES AND DISEASES
    5. Denizot, Y; Raher, S; Trimoreau, F; Praloran, V; Godard, A
      Effect of cytokines and lipid mediators on the synthesis of interleukin 1 beta by human bone marrow stromal cells

      CYTOKINE
    6. Besse, A; Trimoreau, F; Praloran, V; Denizot, Y
      Effect of cytokines and growth factors on the macrophage colony-stimulating factor secretion by human bone marrow stromal cells

      CYTOKINE
    7. Cipolleschi, MG; Rovida, E; Ivanovic, Z; Praloran, V; Olivotto, M; Dello Sbarba, P
      The expansion of murine bone marrow cells preincubated in hypoxia as an invitro indicator of their marrow-repopulating ability

      LEUKEMIA
    8. Desplat, V; Dulery, C; Faucher, JL; Praloran, V; Denizot, Y
      Metabolism and effect of platelet-activating factor on the growth of humanmyeloma cell lines

      CANCER LETTERS
    9. Desplat, V; Besse, A; Denizot, Y; Praloran, V
      Is the COX-2 effect on accelerated hematopoiesis mediated by prostaglandinE-2?

      EXPERIMENTAL HEMATOLOGY
    10. Ivanovic, Z; Dello Sbarba, P; Trimoreau, F; Faucher, JL; Praloran, V
      Primitive human HPCs are better maintained and expanded in vitro at 1 percent oxygen than at 20 percent

      TRANSFUSION
    11. Ivanovic, Z; Bartolozzi, B; Bernabei, PA; Cipolleschi, MG; Rovida, E; Milenkovic, P; Praloran, V; Dello Sbarba, P
      Incubation of murine bone marrow cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors

      BRITISH JOURNAL OF HAEMATOLOGY
    12. Ivanovic, Z; Bartolozzi, B; Bernabei, PA; Cipolleschi, MG; Milenkovic, P; Praloran, V; Dello Sbarba, P
      A simple, one-step clonal assay allows the sequential detection of committed (CFU-CM-like) progenitors and several subsets of primitive (HPP-CFC) murine progenitors

      STEM CELLS
    13. Desplat, V; Besse, A; Faucher, JL; Praloran, V; Denizot, Y
      Expression of platelet-activating factor receptor transcript-1 but not transcript-2 by human bone marrow cells

      STEM CELLS
    14. AVETLOISEAU H; BRIGAUDEAU C; MORINEAU N; TALMANT P; LAI JL; DAVIET A; LI JY; PRALORAN V; RAPP MJ; HAROUSSEAU JL; FACON T; BATAILLE R
      HIGH-INCIDENCE OF CRYPTIC TRANSLOCATIONS INVOLVING THE IG HEAVY-CHAINGENE IN MULTIPLE-MYELOMA, AS SHOWN BY FLUORESCENCE IN-SITU HYBRIDIZATION

      Genes chromosomes & cancer (Print)
    15. Denizot, Y; Godard, A; Raher, S; Trimoreau, F; Praloran, V
      Lipid mediators modulate the synthesis of interleukin 8 by human bone marrow stromal cells

      CYTOKINE
    16. Denizot, Y; Turlure, P; Bordessoule, D; Trimoreau, F; Praloran, V
      Serum IL-10 and IL-13 concentrations in patients with haematological malignancies

      CYTOKINE
    17. Desplat, V; Dulery, C; Praloran, V; Denizot, Y
      Incorporation and effect of arachidonic acid on the growth of human myeloma cell lines

      MEDIATORS OF INFLAMMATION
    18. Denizot, Y; Desplat, V; Dulery, C; Trimoreau, F; Praloran, V
      Arachidonic acid and freshly isolated human bone marrow mononuclear cells

      MEDIATORS OF INFLAMMATION
    19. Le Meur, Y; Lorgeot, V; Aldigier, JC; Wijdenes, J; Leroux-Robert, C; Praloran, V
      Whole blood production of monocytic cytokines (IL-1 beta, IL-6, TNF-alpha,sIL-6R, IL-1Ra) in haemodialysed patients

      NEPHROLOGY DIALYSIS TRANSPLANTATION
    20. Denizot, Y; Dulery, C; Desplat, V; Praloran, V
      Incorporation and effect of arachidonic acid on the growth of the human K562 cell line

      CANCER LETTERS
    21. Besse, A; Trimoreau, F; Faucher, JL; Praloran, V; Denizot, Y
      Prostaglandin E-2 regulates macrophage colony stimulating factor secretionby human bone marrow stromal cells

      BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
    22. Denizot, Y; Besse, A; Raher, S; Nachat, R; Trimoreau, F; Praloran, V; Godard, A
      Interleukin-4 (IL-4), but not IL-10, regulates the synthesis of IL-6, IL-8and leukemia inhibitory factor by human bone marrow stromal cells

      BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
    23. Desplat, V; Petit, B; Trimoreau, F; Praloran, V; Denizot, Y
      EP2 and EP4 receptor subtypes in human bone marrow stromal cells

      BRITISH JOURNAL OF HAEMATOLOGY
    24. TRIMOREAU F; GACHARD N; JACCARD A; TONI FB; BORDESSOULE D; PRALORAN V
      B-CELL COMPARTMENTS IN MULTIPLE-MYELOMA - FLOW CYTOMETRIC ANALYSIS OFTHEIR LABELING INDEXES AND BCL-2 PROTEIN EXPRESSION

      HEMATOLOGY AND CELL THERAPY
    25. Pitard, V; Lorgeot, V; Taupin, JL; Aubard, Y; Praloran, V; Moreau, JF
      The presence in human serum of a circulating soluble leukemia inhibitory factor receptor (sgp190) and its evolution during pregnancy

      EUROPEAN CYTOKINE NETWORK
    26. DUPUIS A; GACHARD N; ALLEGRAUD A; PRALORAN V; DENIZOT Y
      PROSTAGLANDIN E-2 STIMULATES THE GROWTH OF HUMAN BLOOD CD34(+) PROGENITORS

      PROSTAGLANDINS & OTHER LIPID MEDIATORS
    27. MOSSUZ P; DOBO I; GENEVAY MC; ALLEGRAUD A; DAUTEL M; NIAUSSAT AE; COUSIN F; PRALORAN V; BOCCACCIO C; HERMOUET S
      USE OF COLLAGEN FOR STANDARDIZATION OF PBSC GRAFT QUALITY EVALUATION - A MULTICENTER COMPARATIVE-ANALYSIS OF COMMERCIAL COLLAGEN-BASED AND METHYLCELLULOSE-BASED COLONY-FORMING UNIT (CFU) ASSAY KITS

      Journal of hematotherapy
    28. ROUGIER F; CORNU E; PRALORAN V; DENIZOT Y
      IL-6 AND IL-8 PRODUCTION BY HUMAN BONE-MARROW STROMAL CELLS

      Cytokine
    29. DENIZOT Y; TRIMOREAU F; PRALORAN V
      EFFECTS OF LIPID MEDIATORS ON THE SYNTHESIS OF LEUKEMIA INHIBITORY FACTOR AND INTERLEUKIN-6 BY HUMAN BONE-MARROW STROMAL CELLS

      Cytokine (Philadelphia, Pa. Print)
    30. FIXE P; PRALORAN V
      M-CSF - HEMATOPOIETIC GROWTH-FACTOR OR INFLAMMATORY CYTOKINE

      Cytokine
    31. DUPUIS F; GACHARD N; ALLEGRAUD A; DULERY C; PRALORAN V; DENIZOT Y
      EFFECT OF PLATELET-ACTIVATING-FACTOR ON THE GROWTH OF HUMAN ERYTHROIDAND MYELOID CD34(+) PROGENITORS

      Mediators of inflammation
    32. DESPLAT V; DUPUIS F; TRIMOREAU F; DULERY C; PRALORAN V; DENIZOT Y
      EFFECTS OF LIPOXYGENASE METABOLITES OF ARACHIDONIC-ACID ON THE GROWTHOF HUMAN MONONUCLEAR MARROW-CELLS AND MARROW STROMAL CELL-CULTURES

      Mediators of inflammation
    33. PRALORAN V; COMTE L; LEMEUR Y; ALDIGIER JC
      REGULATION OF ERYTHROPOIESIS BY BONE-MARROW RENINANGIOTENSIN SYSTEM -FACTS AND SPECULATIONS

      Experimental hematology
    34. LEMEUR Y; ALDIGIER JC; PRALORAN V
      IS PLASMA AC-SDKP LEVEL A RELIABLE MARKER OF CHRONIC ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN HYPERTENSIVE PATIENTS

      Hypertension
    35. DENIZOT Y; DULERY C; TRIMOREAU F; DESPLAT V; PRALORAN V
      ARACHIDONIC-ACID AND HUMAN BONE-MARROW STROMAL CELLS

      Biochimica et biophysica acta. Molecular cell research
    36. COMTE L; LORGEOT V; BIGNON J; VOLKOV L; DUPUIS F; WDZIECZAKBAKALA J; PRALORAN V
      IN-VIVO MODIFICATIONS OF ACSDKP METABOLISM AND HEMATOPOIESIS IN MICE TREATED WITH 5-FLUOROURACIL AND GORALATIDE

      European journal of clinical investigation
    37. AVETLOISEAU H; LI JY; FACON T; BRIGAUDEAU C; MALOISEL F; TALMANT P; LAI JL; RAPP MJ; PRALORAN V; HAROUSSEAU JL; BATAILLE R
      THE 14Q32 REGION IS FREQUENTLY INVOLVED IN CHROMOSOMAL TRANSLOCATIONSIN MULTIPLE-MYELOMA, ESPECIALLY WITH THE 4P16 AND 11Q13 REGIONS

      British Journal of Haematology
    38. LIOZON E; BRIGAUDEAU C; TRIMOREAU F; DESANGLES F; FERMEAUX V; PRALORAN V; BORDESSOULE D
      IS TREATMENT WITH HYDROXYUREA LEUKEMOGENIC IN PATIENTS WITH ESSENTIALTHROMBOCYTHEMIA - AN ANALYSIS OF 3 NEW CASES OF LEUKEMIC TRANSFORMATION AND REVIEW OF THE LITERATURE

      HEMATOLOGY AND CELL THERAPY
    39. FIXE P; PRALORAN V
      MACROPHAGE COLONY-STIMULATING-FACTOR (M-CSF OR CSF-1) AND ITS RECEPTOR - STRUCTURE-FUNCTION-RELATIONSHIPS

      European cytokine network
    40. LORGEOT V; TRIMOREAU F; GACHARD N; PRALORAN V; DENIZOT Y
      LEUKEMIA INHIBITORY FACTOR CONCENTRATIONS IN THE BONE-MARROW PLASMA OF HEALTHY-SUBJECTS AND PATIENTS WITH HEMATOLOGIC MALIGNANCIES

      European cytokine network
    41. FIXE P; ROUGIER E; OSTYN E; GACHARD N; FAUCHER JL; PRALORAN V; DENIZOT Y
      SPONTANEOUS AND INDUCIBLE PRODUCTION OF MACROPHAGE-COLONY-STIMULATINGFACTOR BY HUMAN BONE-MARROW STOMAL CELLS

      European cytokine network
    42. LORGEOT V; ROUGIER F; FIXE P; CORNU E; PRALORAN V; DENIZOT Y
      SPONTANEOUS AND INDUCIBLE PRODUCTION OF LEUKEMIA INHIBITORY FACTOR BYHUMAN BONE-MARROW STROMAL CELLS

      Cytokine
    43. MAYNADIE M; CAMPOS L; MOSKOVTCHENKO P; SABIDO O; AHO S; LENORMAND B; CARLI PM; GUYOTAT D; BENE MC; FAURE G; CAPIOD JC; GARDAIS J; FEUILLARD J; RAPHAEL M; LACOMBE R; LECALVEZ G; LEGLISE MC; DENEYS V; MASSON AM; BERNIER M; MALET AM; SALAUN C; BOURIN P; RAPATEL C; TAVERNIER F; JOUAULT H; LELONG F; CHRETIEN P; SOLARY E; CASASNOVAS RO; MAYNADIE M; MOSKOVTCHENKO P; FAVRE M; BENSA JC; JACOB MC; WALLEF G; SARIAUX C; TRIMOREAU F; PRALORAN V; CAMPOS L; SABIDO O; VASSELON C; BRUNET C; PONCELET P; GUITARD AM; TAIB J; LAVABREBERTRAND T; JUNG G; KANDEL G; GARAND R; PHILIP P; SUDAKA I; MONPOUX F; VANHAEKE D; PERROT JY; MARIE JP; VALENSI F; VERGE V; HOMBERG JC; SCHAISON G; BOUMSELL L; DOUAY L; SAMSON T; BRIZARD A; DALIPHARD S; DRENOU B; LEES O; LENORMAND B; POILANE B; FALKENRODT A; ALBERT A; KUHLEIN E; ESTIENNE MH; BREMOND JL; DEGENNE M; LEBARON F; REUMAUX G; DUTHILLEUL P; BENE MC; FAURE G; BORDIGONI P; WITZ F; KOLLOPSARDA MN; BAYLE C; ANTONINI J; BOUCHEIX C; CHARPENTIER A
      HETEROGENOUS EXPRESSION OF CD15 IN ACUTE LYMPHOBLASTIC-LEUKEMIA - A STUDY OF 10 ANTI-CD15 MONOCLONAL-ANTIBODIES IN 158 PATIENTS

      Leukemia & lymphoma
    44. ROUGIER F; CORNU E; GACHARD N; PRALORAN V; DENIZOT Y
      TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) STIMULATES THE GROWTH OF HUMAN BONE-MARROW STROMAL CELLS

      Mediators of inflammation
    45. VERGNE P; PRALORAN V; TREVES R; DENIZOT Y
      DECREASED LEVELS OF SERUM PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE IN PATIENTS WITH RHEUMATIC DISEASES

      Mediators of inflammation
    46. DUPUIS F; DESPLAT V; PRALORAN V; DENIZOT Y
      EFFECTS OF LIPIDIC MEDIATORS ON THE GROWTH OF HUMAN MYELOID AND ERYTHROID MARROW PROGENITORS

      Journal of lipid mediators and cell signalling
    47. ROUGIER F; DUPUIS F; CORNU E; DULERY C; PRALORAN V; DENIZOT Y
      PLATELET-ACTIVATING-FACTOR AND ANTAGONISTS MODULATE DNA-SYNTHESIS IN HUMAN BONE-MARROW STROMAL CELL-CULTURES

      Journal of lipid mediators and cell signalling
    48. DENIZOT Y; ROUGIER F; DUPUIS F; TRIMOREAU F; DULERY C; LASKAR M; PRALORAN V
      PRESENCE AND METABOLISM OF LYSO-PLATELET-ACTIVATING-FACTOR IN HUMAN BONE-MARROW

      Journal of lipid mediators and cell signalling
    49. DUPUIS F; ROUGIER F; TRIMOREAU F; OSTYN E; DULERY C; PRALORAN V; DENIZOT Y
      PRODUCTION AND METABOLISM OF PLATELET-ACTIVATING-FACTOR BY HUMAN BONE-MARROW CELLS

      Research in immunology
    50. LORGEOT V; PRALORAN V; TURLURE P; DENIZOT Y
      CONCENTRATIONS OF SERUM LEUKEMIA INHIBITORY FACTOR (LIF) IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

      Leukemia
    51. VOLKOV L; COMTE L; LACROIX P; PRALORAN V
      VARIATIONS OF CELLULAR ACSDKP CONCENTRATIONS DURING THE GROWTH PHASESOF MS-K AND NJE CONTINUOUS CELL-LINES

      The Cancer journal
    52. COMTE L; LORGEOT V; VOLKOV L; ROULLET B; TUBIANA N; PRALORAN V
      ACSDKP PLASMA-CONCENTRATIONS IN PATIENTS WITH SOLID TUMORS - COMPARISON OF 2 CHEMOTHERAPEUTIC REGIMENS

      Cancer letters
    53. CHAMPELOVIER P; FIXE P; VALIRON O; FEIGE JJ; PRALORAN V; SEIGNEURIN D
      PROLIFERATION OF LAMA-84 AND LAMA-87 CELL-LINES IS MODULATED BY AUTOCRINE LOOPS INVOLVING M-CSF AND TGF-BETA

      Experimental hematology
    54. LI J; VOLKOV L; COMTE L; HERVE P; PRALORAN V; CHARBORD P
      PRODUCTION AND CONSUMPTION OF THE TETRAPEPTIDE ACSDKP, A NEGATIVE REGULATOR OF HEMATOPOIETIC STEM-CELLS, BY HEMATOPOIETIC MICROENVIRONMENTAL CELLS

      Experimental hematology
    55. DUPUIS F; LEVASSEUR S; JEANLOUIS F; DULERY C; PRALORAN V; DENIZOT Y; MICHEL L
      PRODUCTION, METABOLISM AND EFFECT OF PLATELET-ACTIVATING-FACTOR ON THE GROWTH OF THE HUMAN K562 ERYTHROID CELL-LINE

      Biochimica et biophysica acta. Molecular cell research
    56. LEMEUR Y; LEROUXROBERT C; PRALORAN V
      WHOLE-BLOOD PRODUCTION OF MONOCYTIC CYTOKINES (IL-1-BETA, IL-1RA, IL-6, IL-6-R, TNF-ALPHA) IN HEMODIALYZED PATIENTS

      Kidney international
    57. COMTE L; LORGEOT V; VOLKOV L; ALLEGRAUD A; ALDIGIER JC; PRALORAN V
      EFFECTS OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ENALAPRIL ON BLOOD HEMATOPOIETIC PROGENITORS AND ACETYL-N-SER-ASP-LYS-PRO CONCENTRATIONS

      European journal of clinical investigation
    58. TRIMOREAU F; VERGER C; PRALORAN V; DENIZOT Y
      NO SEX-RELATED DIFFERENCE IN THE MYELOID ERYTHROID RATIO IN MORPHOLOGICALLY NORMAL BONE-MARROW ASPIRATES/

      British Journal of Haematology
    59. MARTYRE MC; LEBOUSSEKERDILES MC; ROMQUIN N; CHEVILLARD S; PRALORAN V; DEMORY JL; DUPRIEZ B
      ELEVATED LEVELS OF BASIC FIBROBLAST GROWTH-FACTOR IN MEGAKARYOCYTES AND PLATELETS FROM PATIENTS WITH IDIOPATHIC MYELOFIBROSIS

      British Journal of Haematology
    60. BRIGAUDEAU C; TRIMOREAU F; GACHARD N; ROUZIER E; JACCARD A; BORDESSOULE D; PRALORAN V
      CYTOGENETIC STUDY OF 30 PATIENTS WITH MULTIPLE-MYELOMA - COMPARISON OF 3 AND 6 DAY BONE-MARROW CULTURES STIMULATED OR NOT WITH CYTOKINES BYUSING A MINIATURIZED KARYOTYPIC METHOD

      British Journal of Haematology
    61. AVETLOISEAU H; BRIGAUDEAU C; TALMANT P; LAI JL; DAVIET A; PRALORAN V; RAPP MJ; HAROUSSEAU JL; FACON T; BATAILLE R
      HIGH-INCIDENCE OF IG HEAVY-CHAIN GENE (IGH) REARRANGEMENTS WITH VARIOUS PARTNER CHROMOSOMES IN MULTIPLE-MYELOMA, AS SHOWN BY MOLECULAR CYTOGENETICS

      Blood
    62. FRANCOIS B; TRIMOREAU F; VIGNON P; FIXE P; PRALORAN V; GASTINNE H
      THROMBOCYTOPENIA IN THE SEPSIS SYNDROME - ROLE OF HEMOPHAGOCYTOSIS AND MACROPHAGE-COLONY-STIMULATING FACTOR

      The American journal of medicine
    63. BRIGAUDEAU C; GACHARD N; CLAY D; FIXE P; ROUZIER E; PRALORAN V
      A MINIATURIZED METHOD FOR THE KARYOTYPIC ANALYSIS OF BONE-MARROW OR BLOOD-SAMPLES IN HEMATOLOGICAL MALIGNANCIES

      HEMATOLOGY AND CELL THERAPY
    64. DENIZOT Y; ROUGIER F; CORNU E; PRALORAN V
      PLATELET-ACTIVATING-FACTOR AND HEMATOPOIESIS .11. PLATELET-ACTIVATING-FACTOR HAS NO EFFECT ON THE PRODUCTION OF INTERLEUKIN-6 AND TUMOR-NECROSIS-FACTOR-ALPHA BY HUMAN BONE-MARROW STROMAL CELLS

      European cytokine network
    65. DENIZOT Y; FIXE P; TRIMOREAU F; PRALORAN V
      MACROPHAGE-COLONY-STIMULATING FACTOR LEVELS IN THE PLASMA OF BONE-MARROW ASPIRATE IN SEVERAL HEMATOLOGICAL MALIGNANCIES

      Stem cells
    66. LEMEUR Y; LEROUXROBERT C; PRALORAN V
      WHOLE-BLOOD PRODUCTION OF MONOCYTIC CYTOKINES (IL-IP, IL-1RA, IL-6, IL-6-R, TNF-ALPHA) IN HEMODIALYZED PATIENTS

      Journal of the American Society of Nephrology
    67. FIXE P; LORGEOT V; LEMEUR Y; COUPEY L; HEYMANN D; GODARD A; PRALORAN V
      DEVELOPMENT OF ENZYMO-IMMUNOASSAYS (EIA) FOR MACROPHAGE-COLONY-STIMULATING FACTOR (M-CSF) AND LEUKEMIA INHIBITORY FACTOR (LIF) BY USING THESAME CAPTURE AND SIGNAL GENERATING POLYCLONAL ANTIBODY

      Cytokine
    68. HEYMANN D; LHER E; NGUYEN JM; RAHER S; CANFRERE I; COUPEY L; FIXE P; CHAILLEUX E; DEGROOTE D; PRALORAN V; GODARD A
      LEUKEMIA INHIBITORY FACTOR (LIF) PRODUCTION IN PLEURAL EFFUSIONS - COMPARISON WITH PRODUCTION OF IL-4, IL-8, IL-10 AND MACROPHAGE-COLONY-STIMULATING FACTOR (M-CSF)

      Cytokine
    69. DENIZOT Y; DUPUIS F; TRIMOREAU F; VERGER C; ALLEGRAUD A; PRALORAN V
      PAF AND HEMATOPOIESIS .4. PLATELET-ACTIVATING-FACTOR INCREASES DNA-SYNTHESIS IN HUMAN BONE-MARROW CELLS

      Journal of lipid mediators and cell signalling
    70. DUPUIS F; DULERY C; PRALORAN V; DENIZOT Y
      PAF AND HEMATOPOIESIS .12. MACROPHAGE-COLONY-STIMULATING FACTOR (M-CSF) DECREASES PLATELET-ACTIVATING-FACTOR (PAF) ACETYLHYDROLASE PRODUCTION IN MACROPHAGIC J774 CELLS

      Cancer letters
    71. DENIZOT Y; ROUGIER F; DUPUIS F; VERGER C; DULERY C; LASKAR M; ALDIGIER JC; PRALORAN V
      PAF AND HEMATOPOIESIS .8. BIOSYNTHESIS AND METABOLISM OF PAF BY HUMANBONE-MARROW STROMAL CELLS

      Experimental hematology
    72. DUPUIS F; DENIZOT Y; FIXE P; DULERY C; PRALORAN V
      PAF AND HEMATOPOIESIS .10. MACROPHAGE-COLONY-STIMULATING FACTOR AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ENHANCE PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE PRODUCTION BY HUMAN BLOOD-DERIVED MACROPHAGES

      Biochimica et biophysica acta. Molecular cell research
    73. BRIGAUDEAU C; LIOZON E; BERNARD P; TRIMOREAU F; BORDESSOULE D; PRALORAN V
      DELETION OF CHROMOSOME 20Q ASSOCIATED WITH HYPEREOSINOPHILIC SYNDROME- A REPORT OF 2 CASES

      Cancer genetics and cytogenetics
    74. LEMEUR Y; FIXE P; ALDIGIER JC; LEROUXROBERT C; PRALORAN V
      MACROPHAGE-COLONY-STIMULATING FACTOR INVOLVEMENT IN UREMIC PATIENTS

      Kidney international
    75. ROBLEDO O; AUGUSTE P; COUPEY L; PRALORAN V; CHEVALIER S; POUPLARD A; GASCAN H
      BINDING INTERACTIONS OF LEUKEMIA INHIBITORY FACTOR AND CILIARY NEUROTROPHIC FACTOR WITH THE DIFFERENT SUBUNITS OF THEIR HIGH-AFFINITY RECEPTORS

      Journal of neurochemistry
    76. AUGUSTE P; ROBLEDO O; OLIVIER C; FROGER J; PRALORAN V; POUPLARDBARTHELAIX A; GASCAN H
      ALANINE SUBSTITUTION FOR THR(268) AND ASP(269) OF SOLUBLE CILIARY NEUROTROPHIC FACTOR (CNTF) RECEPTOR-ALPHA COMPONENT DEFINES A SPECIFIC ANTAGONIST FOR THE CNTF RESPONSE

      The Journal of biological chemistry
    77. VOLKOV L; QUERE P; COUDERT F; COMTE L; PRALORAN V
      THE TETRAPEPTIDE ACSDKP, A PHYSIOLOGICAL INHIBITOR OF NORMAL-CELL PROLIFERATION, REDUCES THE S-PHASE ENTRY OF CONTINUOUS CELL-LINES

      Experimental cell research
    78. VOLKOV L; QUERE P; COUDERT F; COMTE L; ANTIPOV Y; PRALORAN V
      THE TETRAPEPTIDE ACSDKP, A NEGATIVE REGULATOR OF CELL-CYCLE ENTRY, INHIBITS THE PROLIFERATION OF HUMAN AND CHICKEN LYMPHOCYTES

      Cellular immunology
    79. LEBOUSSEKERDILES MC; CHEVILLARD S; CHARPENTIER A; ROMQUIN N; CLAY D; SMADJAJOFFE F; PRALORAN V; DUPRIEZ B; DEMORY JL; JASMIN C; MARTYRE MC
      DIFFERENTIAL EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA, BASIC FIBROBLAST GROWTH-FACTOR, AND THEIR RECEPTORS IN CD34(+) HEMATOPOIETIC PROGENITOR CELLS FROM PATIENTS WITH MYELOFIBROSIS AND MYELOID METAPLASIA

      Blood
    80. DENIZOT Y; FIXE P; LIOZON E; PRALORAN V
      SERUM INTERLEUKIN-8 (IL-8) AND IL-6 CONCENTRATIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

      Blood
    81. FIXE P; DENIZOT Y; LIOZON E; BORDESSOULE D; PRALORAN V
      SERUM MACROPHAGE-COLONY-STIMULATING FACTOR CONCENTRATIONS IN PATIENTSWITH LYMPHOID AND NONLYMPHOID HEMATOLOGIC MALIGNANCIES

      European cytokine network
    82. PRALORAN V; LEMEUR Y; COUPEY L; RINCE M
      INCREASED LEVELS OF SERUM MACROPHAGE-COLONY-STIMULATING FACTOR (M-CSFOR CSF-1) IN PATIENTS WITH CHRONIC RENAL-INSUFFICIENCY (CRF) - FACTS AND HYPOTHESES

      Cytokine
    83. VANHAEKE DR; BENE MC; GARAND R; FAURE GC; GARDAIS J; LEGLISE MC; LECALVEZ G; BERNIER M; MASSY M; GRIVEAU AM; BROUTARD P; LEBRUN C; BONHOMME J; CHASSAGNE B; DEMEOCQ F; RAPATEL C; TAVERNIER F; JOUAULT H; LELONG F; CHRETIEN P; SOLARY E; CASASNOVAS RO; MAYNADIE M; BENSA JC; FAVRE M; JACOB MC; SARTIAUX C; HUART JL; DROUET M; PRALORAN V; TRIMOREAU F; CAMPOS L; LARESE A; PONCELET P; BESSONFAURE I; BRUNET C; LAVABREBERTRAND T; TAIB J; KANDEL G; JUNG G; HARROUSSEAU JL; PHILIP P; MONPOUX F; BAUDOUIN F; SUDAKA I; CALDANI C; VANHAEKE D; BERNARD A; VALENSI F; BOURIN P; ARBORIO M; SCHAISON G; BOUMSELL L; ADAM M; DOUAI L; BRIZARD A; DALIPHARD S; GENETET N; FAUCHET R; DRENOU B; LEES O; LENORMAND B; VANNIER JP; SABIDO O; GUYOTAT D; VASSELON C; FALKENRODT A; ALBERT A; BREMOND JL; GEORGET MT; KUHLEIN E; LEBARON F; DUTHILLEUL P; REUMAUX F; FAURE G; KOLOPPSARDA MN; BORDIGONI P; WITZ F; BAYLE C; ANTONINI J; CHARPENTIER A
      EXPRESSION AND LONG-TERM PROGNOSTIC VALUE OF CD34 IN CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA

      Leukemia & lymphoma
    84. DENIZOT Y; CHARISSOUX JL; NATHAN N; PRALORAN V
      PAF AND HEMATOPOIESIS .5. PLATELET-ACTIVATING-FACTOR AND ACETYLHYDROLASE IN HUMAN FEMORAL BONE-MARROW

      Journal of lipid mediators and cell signalling
    85. DENIZOT Y; TRIMOREAU F; DUPUIS F; VERGER C; PRALORAN V
      PLATELET-ACTIVATING-FACTOR CONCENTRATIONS IN BONE-MARROW OF PATIENTS WITH LYMPHOID AND NONLYMPHOID HEMATOLOGIC MALIGNANCIES

      Leukemia
    86. DENIZOT Y; DUPUIS F; COMTE L; DULERY C; PRALORAN V
      PAF AND HEMATOPOIESIS .4. MODIFICATIONS OF SPLEEN AND THYMUS PAF CONTENTS AFTER A SINGLE-DOSE OF THE CHEMOTHERAPEUTIC DRUG 5-FLUOROURACIL IN MICE

      Cancer letters
    87. VOLKOV L; COMTE L; FRINDEL E; PHILIPPE M; PRALORAN V
      THE CONCENTRATIONS OF ACSDKP, A PHYSIOLOGICAL INHIBITOR OF CELL-PROLIFERATION, VARY DURING OOGENESIS AND EARLY DEVELOPMENT IN XENOPUS-LAEVIS

      Biology of the cell
    88. DENIZOT Y; TRIMOREAU F; DUPUIS F; VERGER C; PRALORAN V
      PAF AND HEMATOPOIESIS .3. PRESENCE AND METABOLISM OF PLATELET-ACTIVATING-FACTOR IN HUMAN BONE-MARROW

      Biochimica et biophysica acta. Molecular cell research
    89. DENIZOT Y; DUPUIS F; PRALORAN V
      PLATELET-ACTIVATING-FACTOR AND HUMAN BLOOD MONOCYTES - AN OVERVIEW

      Bulletin de l'Institut Pasteur
    90. DENIZOT Y; FIXE P; LIOZON E; BRIGAUDEAU C; PRALORAN V
      SERUM IL-6 CONCENTRATIONS IN LYMPHOMAS

      British Journal of Haematology
    91. LIOZON E; VOLKOV L; COMTE L; TRIMOREAU F; PRADELLES P; BORDESSOULE D; FRINDEL E; PRALORAN V
      ACSDKP SERUM CONCENTRATIONS VARY DURING CHEMOTHERAPY IN PATIENTS WITHACUTE MYELOID-LEUKEMIA

      British Journal of Haematology
    92. LEBOUSSEKERDILES MC; CHARPENTIER A; CHEVILLARD S; ROMQUIN N; CLAY D; SMADJAJOFFE F; PRALORAN V; DUPRIEZ B; DEMORY JL; JASMIN C; MARTYRE MC
      DIFFERENTIAL EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA, BASIC FIBROBLAST GROWTH-FACTOR AND THEIR RECEPTORS IN CD34 HEMATOPOIETIC PROGENITOR CELLS FROM PATIENTS WITH MYELOFIBROSIS AND MYELOID METAPLASIA

      Blood
    93. DENIZOT Y; DUPUIS F; TRIMOREAU F; PRALORAN V; LIOZON E
      DECREASED LEVELS OF PLATELET-ACTIVATING-FACTOR IN BLOOD OF PATIENTS WITH LYMPHOID AND NONLYMPHOID HEMATOLOGIC MALIGNANCIES

      Blood
    94. LEMEUR Y; RINCE M; GUIBERT B; LEROUXROBERT C; PRALORAN V
      ELEVATION OF M-CSF (MACROPHAGE-COLONY-STIMULATING FACTOR) IN UREMIC PATIENTS

      Journal of the American Society of Nephrology
    95. GARAND R; BENE MC; GARDAIS J; DUBOSCMARCHENAY N; LACOMBE F; LEGLISE MC; LECALVEZ G; BERNIER M; MASSY M; GRIVEAU AM; BROUTARD P; LEBRUN C; BONHOMME J; CHASSAGNE B; DEMEOCQ F; RAPATEL C; TAVERNIER F; JOUAULT H; LELONG F; SOLARY E; CASASNOVAS RO; MAYNADIE M; BENSA JC; FAVRE M; JACOB MC; SARTIAUX C; HUART JL; DROUET M; PRALORAN V; TRIMOREAU F; CAMPOS L; LARESE A; PONCELET P; BESSONFAURE I; BRUNET C; LAVABREBERTRAND TL; TAIB J; KANDEL G; JUNG G; HARROUSSEAU JL; PHILIP P; MONPOUX F; BAUDOUIN F; SUDAKA I; CALDANI C; POMIER G; BERNARD A; REGUER M; SCHILL H; BOURIN P; ARBORIO M; SCHAISON G; BOUMSELL L; ADAM M; DOUAI L; VANHAECKE D; BRIZARD A; ROUALET JP; TABARY T; CHAUMAREL I; GENETET N; FAUCHET R; DRENOU B; LEES O; LENORMAND B; VANNIER JP; LEPETIT JC; ACQUART S; SABIDO O; GUYOTAT D; VASSELON C; FALKENRODT A; ALBERT A; BREMOND JL; GEORGET MT; ROUBINET F; KUHLEIN E; LEBARON F; DUTHILLEUL P; REUMAUX F; FAURE G; KOLOPPSARDA MN; BORDIGONI P; WITZ F; BAYLE C; ANTONINI J; CHARPENTIER A
      A NEW APPROACH OF ACUTE LYMPHOBLASTIC-LEUKEMIA IMMUNOPHENOTYPIC CLASSIFICATION - 1984-1994 THE GEIL EXPERIENCE

      Leukemia & lymphoma
    96. DENIZOT Y; PRALORAN V
      PAF AND HEMATOPOIESIS .1. 5-FLUORO-URACIL INDUCES PAF PRODUCTION IN HEMATOPOIETIC ORGANS OF RATS

      Mediators of inflammation
    97. DENIZOT Y; DUPUIS F; PRALORAN V
      EFFECTS OF PLATELET-ACTIVATING-FACTOR ON HUMAN T-CELLS AND B-CELLS - AN OVERVIEW

      Research in immunology
    98. CHEVALIER S; PRALORAN V; YANCOPOULOS GD; POUPLARD A; GASCAN H
      EXPRESSION AND FUNCTIONALITY OF THE TRKA PROTOONCOGENE PRODUCT IN UNDIFFERENTIATED HEMATOPOIETIC-CELLS

      Journal of cellular biochemistry
    99. DENIZOT Y; DUPUIS F; ROULLET B; PRALORAN V
      PAF AND HEMATOPOIESIS .2. ELEVATED LEVELS OF PLASMA PAF ACETYLHYDROLASE AFTER RAPID INFUSION OF 5-FLUOROURACIL IN CANCER-PATIENTS

      Cancer letters
    100. BENAHMED M; BLOTTIERE H; PRALORAN V; DACULSI G
      MONOCYTE ACTIVITY IN THE PRESENCE OF CALCIUM-PHOSPHATE ACTIVATED BY 1,25 (OH)(2) VD3 AND INTERFERON-GAMMA

      Biomaterials


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 13:15:42